賴 吾為

Medicine & Life Sciences

1. Lung Neoplasms 100%
2. Esophageal Squamous Cell Carcinoma 77%
3. Adenocarcinoma of Lung 67%
4. Caustics 64%
5. Non-Small Cell Lung Carcinoma 59%
6. Neoplasms 56%
7. Lung 52%
8. Malignant Pleural Effusion 46%
9. Survival 42%
10. Video-Assisted Thoracic Surgery 36%
11. Quality of Life 28%
12. Thymoma 28%
13. Wounds and Injuries 27%
14. Thymic epithelial tumor 24%
15. Biomarkers 23%
16. Acids 22%
17. Thoracotomy 22%
18. ErbB Receptors 21%
19. Chemoradiotherapy 20%
20. Life Expectancy 20%
21. Cell Movement 19%
22. Esophagus 19%
23. Therapeutics 18%
24. Pulmonary Tuberculosis 18%
25. Quality-Adjusted Life Years 18%
26. Protein-Tyrosine Kinases 18%
27. Drug Therapy 18%
28. Intensity-Modulated Radiotherapy 17%
29. Pathologic Constriction 17%
30. Segmental Mastectomy 17%
31. Pleural Effusion 16%
32. Proteins 15%
33. Cost-Benefit Analysis 14%
34. Mortality 14%
35. Exocytosis 13%
36. Cohort Studies 13%
37. Cell Line 13%
38. Carcinoma 13%
39. Costs and Cost Analysis 13%
40. Fistula 12%
41. Systemic Lupus Erythematosus 12%
42. Genes 12%